Advancing Integrity and Ethics in Montana Healthcare

RESOURCE LIBRARY

RESOURCES

Resources are provided for educational purposes and may include primary research, government documents, professional statements, legal opinions, and other materials representing differing types and levels of evidence. Inclusion does not necessarily constitute endorsement of every conclusion or interpretation contained in a source. Readers are encouraged to review original materials, consider study design and limitations, and discuss individual medical decisions with a qualified healthcare professional. This resource guide does not provide medical or legal advice.

Use the Type and Topic filters on their own or together. Click a selected filter again, or choose All, to clear it.

Type

Topic

Montana House Bill 702 (2021): Vaccine-Status Nondiscrimination

Sponsor: Rep. Jennifer Carlson

Status: Signed May 7, 2021

HB 702 added vaccination status and possession of an immunity passport as protected categories under the Montana Human Rights Act. It generally prohibits discrimination in employment and public accommodations based on vaccination status and limits employer vaccination requirements, subject to statutory exceptions and federal preemption. The law applies beyond COVID-19 vaccination and includes provisions addressing healthcare facilities and schools.

Legal Status Note: A federal district court initially enjoined application of portions of the law in certain healthcare settings. In 2024, the U.S. Court of Appeals for the Ninth Circuit reversed that judgment, allowing the state protections to apply subject to controlling federal requirements.

Montana Law | Vaccine Choice | Informed Consent | Employment | Nondiscrimination | Healthcare Mandates

Montana Senate Bill 99 (2023): Youth Health Protection Act

Sponsor: Sen. John Fuller

Status: Signed April 28, 2023; enforcement permanently enjoined

SB 99 prohibits specified puberty blockers, cross-sex hormones, and surgical procedures when provided to a minor for the purpose of treating gender dysphoria or facilitating a gender transition. The act also provides for professional discipline and restrictions on public funding. Comparable medications and procedures may remain available to minors for other diagnoses or medical purposes specified in the law.

Legal Status Note: In Cross v. State, the Montana Supreme Court affirmed a preliminary injunction in December 2024, holding that the district court did not abuse its discretion in finding that SB 99 likely violated Montana's constitutional right to privacy. On May 13, 2025, the Fourth Judicial District Court granted summary judgment against the State and permanently enjoined enforcement of SB 99. The State announced that it would appeal and pursued post-judgment relief. As of October 2026, the permanent injunction remains in effect and SB 99 is not enforceable. Read Cross v. State 2024 MT 303: https://law.justia.com/cases/montana/supreme-court/2024/da-23-0572-0.html

Montana Law | Pediatric Gender Medicine | Minors | Puberty Blockers | Cross-Sex Hormones | Surgery | Constitutional Litigation | Medical Privacy

Montana House Bill 303 (2023): Medical Ethics and Diversity Act

Sponsor: Rep. Amy Regier

Status: Signed May 3, 2023

HB 303 protects medical practitioners, healthcare institutions, and healthcare payers that decline participation in a healthcare service because of ethical, moral, or religious convictions. The law also provides protections involving professional speech, whistleblowing, adverse licensing or employment action, civil immunity, and legal remedies. It does not authorize objection based on a patient’s personal characteristics; the protected objection must concern participation in the healthcare service itself.

Montana Law | Conscience Rights | Clinician Free Speech | Religious Liberty | Whistleblower Protection | Medical Ethics

Montana House Bill 682 (2025): Gender Transition Treatment and Detransition Coverage

Sponsor: Rep. Greg Kmetz

Status: Signed May 13, 2025; Chapter 709

Effective Date: October 1, 2026, for the primary provisions

HB 682 revises the statute of limitations for civil actions involving gender transition treatment performed on minors. It also establishes reciprocal coverage requirements so that specified private insurance, public employee plans, the Montana University System, Medicaid, and Healthy Montana Kids cover qualifying detransition treatment when they provide or previously provided coverage for gender transition treatment. The law addresses access to remedial care and accountability for alleged long-term injury following interventions received as a minor.

Montana Law | Pediatric Gender Medicine | Detransition Care | Medical Liability | Insurance Coverage | Informed Consent

The Effect of State Bans on Gender Interventions for Minors on Teen Suicide Rates

Jay Greene, Ian Kingsbury

Do No Harm

Published 2026

Using CDC mortality data from 2018 through 2024 and three statistical approaches, this report found no statistically significant increase in completed suicide rates among teenagers following state restrictions on gender-related medical interventions for minors. Important limitations include the use of population-level data not specific to youth with gender dysphoria, short post-policy follow-up, an age band that includes some legal adults, and measurement of completed suicide rather than suicidal ideation or attempts. The report is organizational research and has not undergone journal peer review.

Pediatric Gender Medicine | Suicide | State Policy | Puberty Blockers | Cross-Sex Hormones

Neurodevelopmental Disorder Associated with Aluminum-Adsorbed Vaccines: Reanalysis of Data from a Danish Nationwide Cohort Study

Secondary Data Reanalysis

Karl Jablonowski, Brian Hooker

Integrative Medicine

Published August 2026

This article reexamines data and supplemental analyses from a Danish nationwide cohort study of aluminum-adsorbed vaccines and neurodevelopmental outcomes. The authors argue that selected updated analyses show dose-associated signals and do not support the original study’s no-increased-risk conclusion. This is a secondary reanalysis rather than an independent cohort study; its conclusions should be considered alongside the original publication, which reported no increased risk, and the subsequent corrections and supplemental analyses.

Vaccine Safety | Aluminum Adjuvants | Neurodevelopmental Outcomes | Autism | Research Transparency

Real-time Pharmacovigilance and Cardiac Risk Communication during the COVID-19 Vaccination Campaign in Israel

Yaakov Ophir, Yaffa Shir-Raz

EXCLI Journal

Published September 3, 2026

DOI: 10.17179/excli2026-9596

This article analyzes an internal Israeli Ministry of Health dataset containing 531 hospitalization records and 67 unique deaths reported to Pfizer from March 2021 through May 2022, and examines the timing of public cardiac-risk communications. Myocarditis and pericarditis reports were concentrated among younger people. Because the dataset is descriptive and lacks a population denominator or an unvaccinated comparison group, it cannot establish incidence, population risk, or causality; completeness, case validation, and reporting bias are additional limitations.

COVID-19 Vaccines | Pharmacovigilance | Myocarditis | Risk Communication | Informed Consent

Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19

Tracy B. Høeg, Ram Duriseti, Vinay Prasad; with a reply from Ronen Arbel and colleagues

New England Journal of Medicine

Published July 20, 2023

DOI: 10.1056/NEJMc2306683

This correspondence questions whether healthy-vaccinee bias affected an Israeli observational estimate of BNT162b2 booster effectiveness. The letter notes that booster recipients also had markedly lower mortality from causes unrelated to COVID-19, suggesting substantial baseline health differences between groups. In reply, the original investigators analyzed additional covariates, including hospitalization, and reported that adjustment reduced but did not eliminate the association. The exchange illustrates the risk of residual confounding in observational vaccine-effectiveness studies; it does not independently determine booster efficacy.

COVID-19 Vaccines | Vaccine Effectiveness | Healthy Vaccinee Bias | Observational Research | Confounding

National Institutes of Health / NCBI Bookshelf

NIH / National Library of Medicine

A searchable collection of biomedical books, reports, guidelines, and other full-text health-science resources.

U.S. Food and Drug Administration

FDA

Primary regulatory source for drug and biologic approvals, safety communications, prescribing information, advisory-committee materials, and regulatory review documents.

ClinicalTrials.gov

U.S. National Library of Medicine

A registry and results database for publicly and privately supported clinical studies conducted in the United States and internationally.

Cochrane Library

Cochrane

A collection of systematic reviews and other evidence resources focused on healthcare interventions and clinical decision-making.